Microbial cell lines suitable for industrial-scale production of organic acids and methods of making and isolating such cell lines.

The present invention is related to a method of reducing tobacco addiction in a smoking subject with Lactobacillus fermentum GKF3, including daily administering an oral composition containing the Lactobacillus fermentum GKF3 to the smoking subject, in which the oral composition reduces the total amount of the nicotine metabolites in urine.

Methods of standardizing a fermentation process may include obtaining a fluidic sample, measuring one or more physical parameters of the sample, comparing the measurement of the physical parameter of the material to a baseline value of the physical parameter for the fermentation process, and responsive to a deviation of the measurement of the physical parameter from the baseline value, determining a remediation action based on a correlation between the physical parameter and regulatory genes of a fermentation organism.

An isolated and purified lactic acid bacteria is provided, which is Lactobacillus paracasei PS23 (PS23) and its applications in delaying aging process, improving immunomodulatory activity, reducing, preventing or treating allergic and inflammation, preventing or treating a chronic disorder and/or (vi) preventing and/or treating a mood disorder or a neurological condition.

The present invention relates to lactic acid bacterial strains which are capable of producing or inducing the production of melatonin, for use in the production of melatonin in a subject. Preferred strains for such uses are capable of producing or inducing the production of adenosine. Therapeutic uses of such strains include the treatment or prevention of diseases associated with melatonin deficiency, for example infantile colic. Novel strains are also provided.

The present invention discloses an application of a medical cell CMU-pb-7 in preparation of blood lipid-lowering drugs, which belongs to the technical field of biology. The medical cell CMU-pb-7 disclosed by the present invention is a newly discovered strain of Lactobacillus rhamnosus, having a collection number of CCTCC NO: M 2022220. The medical cell CMU-pb-7 of the present invention can relieve impaired glucose tolerance caused by a high-fat diet in mice with hyperlipidemia, reduce the blood lipid level, enhance the antioxidant capacity of the liver tissue, and regulate the expression of key proteins of liver lipid metabolism to relieve fatty change caused by a high-fat diet. The medical cell CMU-pb-7 disclosed by the present invention has a great potential application prospect in preparation of blood lipid-lowering drugs.

The present invention discloses an anti-aging composition, which includes: (a) isolated lactic acid bacterial strains or a fermented product thereof; and (b) an excipient, a diluent, or a carrier; wherein the isolated lactic acid bacterial strains include: Bifidobacterium bifidum VDD088 strains, Bifidobacterium breve Bv-889 strains, and Bifidobacterium longum BLI-02 strains. The present invention further provides a method for preventing aging by administering the foregoing anti-aging composition to a subject in need thereof.

The present invention relates to: a novel Lactobacillus intestinalis YT2 strain (deposition number: KCCM11812P); and a composition for preventing, alleviating, or treating menopause, comprising, as an active ingredient, Lactobacillus intestinalis comprising the novel strain. The present inventors have established an animal model for menopause through ovariectomy, confirmed changes of the distribution of intestinal microorganisms by the model, identified and isolated a novel Lactobacillus intestinalis strain among lactic acid bacteria of which the distribution is significantly reduced in the menopausal model, and confirmed effects, by means of the novel strain and previously reported Lactobacillus intestinalis strains, of alleviating menopausal symptoms, such as the inhibition of an increase in body fat, the inhibition of a decrease in bone mineral density, the inhibition of an increase in the pain sensitivity, and the alleviation of depression. Therefore, it is expected that the composition comprising the Lactobacillus intestinalis according to the present invention can be usable for a use of preventing, alleviating, or treating menopause.

A Lactobacillus paracasei and uses thereof. The Lactobacillus paracasei has a deposit number of CGMCC No. 14813. The Lactobacillus paracasei can be used for increasing the amount of an organic acid in a raw material. The Lactobacillus paracasei can be used for fermenting the raw material, where the raw material can be selected from at least one of fruits, which can increase the content of the organic acid in a fermented product.

A method for producing a cheese with reduced amount of galactose comprising inoculating milk with Streptococcus thermophilus Gal(+) bacteria and Lactobacillus Gal(+) Lac(?) bacteria.